Integrative Bioinformatics Analysis Identifies DDX60 as a Potential Biomarker for Systemic Lupus Erythematosus

Figure 3

DDX60 expression levels of different subgroups according to SLE Disease Activity Index (SLEDAI), anti-dsDNA, complement component C3 (C3) level, and complement component C4 (C4) level in GSE88884 and GSE121239. (a) DDX60 expression levels of the four subgroups that were distinguished according to the number of positive indicators (SLEDAI ≥ mild active, anti-dsDNA = “positive,” C3 = “low,” and C4 = “low”). ; ; ; ; error bars show the standard deviation of the mean. (b) DDX60 levels in patients with inactive SLE (0 ~ 4), mild active (5 ~ 9), moderate active (10~ 14), and severe active SLE (≥15) of GSE88884. (c) DDX60 levels in the negative or positive anti-dsDNA subgroups of GSE88884. (d, e) DDX60 levels in patients with low C3/C4 level and normal or high level from GSE88884. (f) DDX60 expression level in systemic lupus erythematosus (SLE) patients is significantly higher than in healthy controls (HC) from GSE121239 (). (g) The expression levels of DDX60 of patients with the SLEDAI scores 10-14 and 5-9 are significantly higher than those of score 0-4 () from GSE121239. Box-whisker plots show median, interquartile range, nonoutlier range, and outliers.

(a)

(b)

(c)

(d)

(e)

(f)

(g)